$APP

Valenzuela Victoria sold $11.3M of APP

Valenzuela Victoria (CALO & Corp. Secretary) sold 20,000 shares of AppLovin Corp (APP) at an average of $565.89 ($555.63–$586.49, $11.32M total) across 29 trades on 2026-06-04.

Original reporting
SEC EDGAR · Valenzuela Victoria
Published Jun 8, 2026, 8:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$APP
Neutral
medium confidence
Mentioned
$APP
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APPNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with broader tape/earnings expectations, but the filing alone does not introduce new operating information.

02

Market read

A large officer open-market sale (~$11.3M) is newly disclosed, which can slightly pressure sentiment but lacks a fundamental catalyst in the text.

03

What to watch

The trades span a price range ($555.63–$586.49) across 29 executions, suggesting execution strategy rather than a single-timestamp signal.

Relevance 7/10Novelty 5/10Timing: Filed 2026-06-08; transaction executed 2026-06-04.

Background

The article is an SEC Form 4 insider transaction disclosure for AppLovin, filed by an officer (position: CALO & Corp. Secretary).

Company-level read

Ticker impact

$APPNeutralMedium confidence
Context

AppLovin disclosed an officer open-market sale of 20,000 shares (~$11.32M) on 2026-06-04 via SEC Form 4.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than a new fundamental catalyst.

Evidence & confidence

The filing is a primary-source Form 4 showing a large sale, but it provides no accompanying company-specific negative news (e.g., guidance cut, legal/regulatory action).

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/tax-related and not tied to outlook; the absence of a 10b5-1 plan is a detail but still doesn’t confirm bearish intent.

Key entities

  • AppLovin Corp

    Subject of the Form 4 insider sale disclosure.

  • Valenzuela Victoria

    Officer reporting the open-market sale of APP shares.

Related articles

$APPMed

Applovin stock hits 52-week low at 341.42 USD

AppLovin shares fell to near a 52-week low around $341 to $343, down about 38% year-to-date, according to Investing.com. The article cites Q2 2026 revenue of $1.92B vs $1.95B expected and current-quarter guidance midpoint of $2.07B vs $2.08B. Several analysts cut price targets or ratings after the misses.

$APPMedAI 8/10

AppLovin (APP) Stock Trades Down, Here Is Why

AppLovin (NASDAQ: APP) shares fell 18.6% after the company reported Q2 2026 results below expectations. Revenue was $1.92B versus $1.95B estimates, and Q3 guidance was $2.07B versus $2.08B consensus, according to the company and analysts. Wells Fargo and Piper Sandler downgraded the stock, citing the revenue miss and growth concerns.

$APPMed

Dow slips, Nasdaq moves level as earnings keep markets on edge

U.S. stocks opened mixed as investors digested earnings and economic data. AppLovin (APP) fell over 20% after Q2 revenue of $1.924B missed estimates. Datadog (DDOG) dropped over 18% on weaker bookings and guidance. SpaceX (SPCX) rose about 2.5% after a lockup expiry. Western Digital (WDC) slid 11% on margin outlook; Fiserv (FI) and Kenvue (KVUE) also fell.

$APPMedAI 8/10

Why AppLovin Stock Tumbled Today

AppLovin (NASDAQ: APP) shares fell about 19.6% in early trading after the company reported Q2 results that missed expectations. Revenue rose 53% to $1.92B versus $1.94B consensus. GAAP EPS increased to $3.76, slightly above $3.75. Q3 revenue guidance of $2.055B-$2.085B and adjusted EBITDA outlook also trailed consensus.